VanEck Associates’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
VanEck Associates's PTGX Position: Q3 2026 in Review
VanEck Associates opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 5,551 shares worth $782K. The stake represents ﹤0.01% of the portfolio and ranks #1165 among its holdings.
379 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- VanEck Associates held 5,551 shares of Protagonist Therapeutics worth $782K as of Q3 2026.
- Protagonist Therapeutics was a new VanEck Associates position in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of VanEck Associates's portfolio in Q3 2026, its #1165 holding.
- 379 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on VanEck Associates's 13F filing for Q3 2026, filed 13 Nov 2026.